 MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 GLOBE NEWSWIRE -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. Nasdaq: ASMB today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus HBV infection. A single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial will evaluate ATI-2173, Antios investigational proprietary active site polymerase inhibitor nucleotide ASPIN, vebicorvir VBR, Assembly Bios investigational lead core inhibitor candidate, and tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor. 